Nick joined Sofinnova BioEquities as an Analyst in 2025. He focuses on public investments in global biotechnology and pharmaceutical companies.
Prior to joining Sofinnova, Nick spent over four years on the sell side covering SMid and Large Cap Biotechnology. Most recently, Nick was a Vice President at J.P. Morgan covering Large Cap Biotechnology.
Nick earned his M.A in Biotechnology from Columbia University and B.A. in Chemistry from Kenyon College.